Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.

Clinical Trial Description

C134 is a genetically engineered herpes simplex virus or "HSV" (the virus that usually causes cold sores and rarely, a severe infection of the brain). It has been known that viruses may kill tumor cells. When tumor cells are mixed with certain viruses in the laboratory, the tumor cells die. The DNA of the (HSV) virus has been modified so that tumor cells may be killed when infected by C134. The changes made to the virus (HSV) should help prevent the (C134) virus from infecting normal brain tissue. Extensive testing in both mice and monkeys has demonstrated that C134 is not able to cause HSV when injected directly into the brain. C134 may also be able to help kill tumor cells because it can prevent tumor cells from killing it more effectively than other, similar viruses can. This allows it to infect and kill more brain tumor cells. C134 has been tested in more than ten patients previously. The virus has had only two instances of known significant toxicities. In one patients with extensive disease present on both sides of the brain, the virus traveled throughout the brain and as a result, caused extensive inflammation that required treatment with an antiviral drug. The patient recovered partially, but eventually succumbed to their tumor. A second patient developed an infection of the retina (back of the eye) apparently as a result of the virus migrating to that area from the site of inoculation in the occipital lobe. Based on these findings the investigators have amended the protocol to protect future patients from these toxicities as follows: 1) The dose of the virus being administered has been lowered; 2) patients with enhancing tumor on both sides of the brain are not eligible for the trial and 3) patients with disease in the occipital lobe which has connections to the retina are not eligible for the trial Based on laboratory testing, the investigators believe multiple doses of C134 viral therapy in cases such as the patients, could potentially benefit from repeat treatment as this has been seen in preclinical studies, since the patients have received C134, the patients are thus eligible for retreatment under this protocol. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06193174
Study type	Interventional
Source	University of Alabama at Birmingham
Contact	Norma Miller, RN
Phone	2059756169
Email	ncmiller@uabmc.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	August 1, 2025
Completion date	August 14, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03657576` - Trial of C134 in Patients With Recurrent GBM	Phase 1
Recruiting	`NCT05685004` - Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)	Phase 2/Phase 3
Recruiting	`NCT05076513` - Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma	Early Phase 1
Active, not recruiting	`NCT03665545` - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	Phase 1/Phase 2
Completed	`NCT02474966` - Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study	Phase 2
Active, not recruiting	`NCT02137759` - MRSI to Predict Response to RT/TMZ ± Belinostat in GBM	Phase 2
Enrolling by invitation	`NCT03170141` - Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme	Phase 1
Recruiting	`NCT04842513` - Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma	Phase 1
Recruiting	`NCT04869449` - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas	Early Phase 1
Recruiting	`NCT03633552` - Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma	Phase 3
Not yet recruiting	`NCT05095441` - A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma	Phase 1
Completed	`NCT00003456` - Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme	Phase 2
Completed	`NCT03047473` - Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 2
Enrolling by invitation	`NCT05116137` - The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors	N/A
Recruiting	`NCT05627323` - CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma	Phase 1
Active, not recruiting	`NCT04968366` - Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery	Phase 1
Suspended	`NCT04222309` - Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)	Phase 1
Not yet recruiting	`NCT06186440` - Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT06283927` - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting	`NCT06146725` - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)